4.4 Article

First three Escherichia coli isolates harbouring mcr-1 in Uruguay

期刊

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
卷 20, 期 -, 页码 187-190

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2019.07.016

关键词

E. coli; Colistin resistance; mcr-1; IncX4

资金

  1. Fondo Maria Vinas, Agencia Nacional de Investigacion e Innovacion (ANII)

向作者/读者索取更多资源

Objective: This report described the first Escherichia coli (E. coli) isolates harbouring mcr-1 in Uruguay. Methods: Three E. coli isolates were obtained from blood, urine and rectal swabs from different patients in two hospitals. Extended-spectrum beta-lactamases (ESBL), plasmid-encoded (pAmpC) beta-lactamases, plasmid-mediated quinolone resistance (PMQR) genes, class 1 integrons, and mcr-1, mcr-2 and mcr-3 were sought and characterised in three E. coli isolates. Transfer of resistance determinants was assessed by conjugation. Clonality was analysed by multilocus sequence typing. Results: All isolates were categorised as being colistin-resistant and the mcr-1 gene was detected. Two isolates were also resistant to oxyimino cephalosporins: one on account of bla(CMY-2) and the other due to bla(CTX-M-15), the latter also harbouring transferable quinolone-resistance genes (aac(6')Ib-cr and qnrB). All mcr-1 genes were transferred by conjugation to recipient strains. The mcr-1-bearing isolates belonged to sequence types ST10, ST93 and ST5442. Conclusions: ST10 is considered as a high-risk clone worldwide. This type of mcr-1-harbouring clone is a major concern for human and animal health and must be under close surveillance. This study detected the presence of mcr-1 for the first time in Uruguay, albeit in an allodemic manner, associated with different antibiotic-resistance genes and from diverse clinical contexts. Considering that colistin is often the last therapeutic option available for multidrug-resistant Gram-negative bacilli infections, it is important to maximise precautions to avoid dissemination of isolates carrying mcr-1. (C) 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据